标题
Isorhamnetin protects against cardiac hypertrophy through blocking PI3K–AKT pathway
作者
关键词
Isorhamnetin, Cardiac hypertrophy, PI3K, AKT, Pressure overload
出版物
MOLECULAR AND CELLULAR BIOCHEMISTRY
Volume 429, Issue 1-2, Pages 167-177
出版商
Springer Nature
发表日期
2017-02-07
DOI
10.1007/s11010-017-2944-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Novel Role for Caspase-Activated DNase in the Regulation of Pathological Cardiac Hypertrophy
- (2015) L. Gao et al. HYPERTENSION
- Isorhamnetin Attenuates Atherosclerosis by Inhibiting Macrophage Apoptosis via PI3K/AKT Activation and HO-1 Induction
- (2015) Yun Luo et al. PLoS One
- Vinexin-β protects against cardiac hypertrophy by blocking the Akt-dependent signalling pathway
- (2013) Ke Chen et al. BASIC RESEARCH IN CARDIOLOGY
- Growth/differentiation factor 1 alleviates pressure overload-induced cardiac hypertrophy and dysfunction
- (2013) Yan Zhang et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- O-methylated flavonol isorhamnetin prevents acute inflammation through blocking of NF-κB activation
- (2013) Ji Hye Yang et al. FOOD AND CHEMICAL TOXICOLOGY
- Role of Interferon Regulatory Factor 4 in the Regulation of Pathological Cardiac Hypertrophy
- (2013) Ding-Sheng Jiang et al. HYPERTENSION
- Interferon Regulatory Factor 9 Protects Against Cardiac Hypertrophy by Targeting Myocardin
- (2013) Ding-Sheng Jiang et al. HYPERTENSION
- Isorhamnetin Protects against Doxorubicin-Induced Cardiotoxicity In Vivo and In Vitro
- (2013) Jing Sun et al. PLoS One
- Isorhamnetin protects against oxidative stress by activating Nrf2 and inducing the expression of its target genes
- (2013) Ji Hye Yang et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- mTOR signalling: the molecular interface connecting metabolic stress, aging and cardiovascular diseases
- (2012) Z. Yang et al. Obesity Reviews
- Isorhamnetin Suppresses Skin Cancer through Direct Inhibition of MEK1 and PI3-K
- (2011) J.-E. Kim et al. Cancer Prevention Research
- Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
- (2011) Toshinori Aoyagi et al. CURRENT PHARMACEUTICAL DESIGN
- Isorhamnetin inhibits H2O2-induced activation of the intrinsic apoptotic pathway in H9c2 cardiomyocytes through scavenging reactive oxygen species and ERK inactivation
- (2011) Bing Sun et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways
- (2011) C.F.M.Z. Clemente et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Reverse remodeling in heart failure—mechanisms and therapeutic opportunities
- (2011) Norimichi Koitabashi et al. Nature Reviews Cardiology
- Novel therapeutic targets for the treatment of heart failure
- (2011) Juan Tamargo et al. NATURE REVIEWS DRUG DISCOVERY
- The Role of MEKK1 in Hypertrophic Cardiomyopathy
- (2010) John P. Konhilas et al. International Heart Journal
- Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling
- (2010) Wen Ai et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Isorhamnetin protects rat ventricular myocytes from ischemia and reperfusion injury
- (2009) Najuan Zhang et al. EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY
- LY294002 inhibits leukemia cell invasion and migration through early growth response gene 1 induction independent of phosphatidylinositol 3-kinase-Akt pathway
- (2008) Peng Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis
- (2008) P H Sugden et al. BRITISH JOURNAL OF PHARMACOLOGY
- Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3β signaling
- (2008) Qizhu Tang et al. JOURNAL OF MOLECULAR MEDICINE-JMM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started